The abstract submission system is now closed!
View the abstracts in the online programme
Abstract submission deadlines
Abstracts |
Deadline |
|---|---|
|
Abstracts Trial in Progress Intent to submit LBA |
Tuesday, 13 February 2024, 21:00 CET |
Late-breaking abstracts (LBA) |
Wednesday, 17 April 2024, 21:00 CEST |
Outcome notifications
Outcome notifications of regular abstracts are expected to be made available to first authors and submitters by mid-March 2024.
Outcome notifications of accepted full LBAs are expected to be made available to first authors and submitters by end-April 2024.
Information for presenters
Detailed instructions for the preparation of slide presentations and/or posters will be made available by end-March in the section “Information for Presenters”.
Abstract submission categories
- Biomarkers and translational research and precision medicine
- Early breast cancer: Systemic treatments
- Early breast cancer: Surgery and radiotherapy
- Early detection, hereditary breast cancer and prevention
- Metastatic breast cancer
- Supportive care and survivorship
- Miscellaneous
Late-breaking abstracts
Late-breaking abstracts may be submitted for high quality, new research findings with implications for clinical practice or understanding of disease processes.
The final late-breaking abstract deadline of 17 April 2024 is under no circumstances to be considered as an extension of the general submission deadline (13 February 2024).
Trial in Progress abstracts
Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to ESMO Breast Cancer 2024.
It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis.
Presentation and publication of accepted abstracts
The Breast Cancer 2024 Scientific Committee will select abstracts for presentation during the Congress and determine the format of the presentations from the following possibilities:
- Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
- Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
- Poster – Display session for review, discussion and questions. The presenting authors must be available for Q&A to represent their work.
All accepted abstracts, including Late-breaking, will be published online in the ESMO Breast Cancer 2024 Abstract Book, a supplement to the official ESMO journal, ESMO Open.
Publication schedule of accepted abstracts
Details regarding the publication of accepted abstracts are available here.
ESMO Merit Travel Grant
A restricted number of ESMO Merit Travel Grants to the ESMO Breast Cancer 2024 have been made available (upon application), and awarded to the following abstract presenters:
- Elisa Agostinetto, Bruxelles, BE
- Alison Antoine, Lyon, FR
- Roberto Borea, Genoa, IT
- Kristien Borremans, Leuven, BE
- Michele Bottosso, Padua, IT
- Antonio Di Meglio, Villejuif, FR
- Nan Ding, Maastricht, NL
- Isabel Garcia Fructuoso, Barcelona, ES
- Federica Giugliano, Villejuif, FR
- Manar Hamed, Elmahalla Elkobra, EG
- Karl Harborg, Aarhus, DK
- Julia Caroline Michaeli, Munich, DE
- Chiara Molinelli, Genoa, IT
- Stefania Morganti, Boston, MA, USA
- Simone Nardin, Genoa, IT
- Leonardo Provenzano, Milan, IT
- Constantinos Savva, Southampton, UK
- Benjamin Verret, Villejuif, FR
- Guillermo Villacampa Javierre, Barcelona, ES
- Noelle Vrancken Peeters, Amsterdam, NL